May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

High dose filgotinib meets ulcerative colitis endpoints
A 200 mg dose of filgotinib from Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) met the primary endpoints in the placebo-controlled Phase IIb/III SELECTION trial to treat moderate-to-severe ulcerative colitis, including clinical remission at Week 10 and maintaining clinical remission at Week 58. A 100 mg dose of the JAK1 inhibitor did not achieve statistically significant clinical remission at Week 10.

Expanded FDA labels for Lynparza, Tecentriq
FDA has announced expanded labels for two high-profile cancer drugs: Lynparza olaparib for metastatic castration-resistant prostate cancer in patients with BRCA1/2 and ATM homologous recombination repair (HRR) gene-mutations; and Tecentriq atezolizumab for first-line metastatic non-small cell lung cancer in patients without EGFR or ALK mutations who have high PD-L1 expression. AstraZeneca plc (LSE:AZN; NYSE:AZN) and Merck & Co. Inc. (NYSE:MRK) market Lynparza, a PARP inhibitor; Roche (SIX:ROG; OTCQX:RHHBY) markets PD-L1 inhibitor Tecentriq...